Henze T, Feneberg W, Flachenecker P, Seidel D, Albrecht H, Starck M, Meuth S G
Praxisgemeinschaft für Neurologie, Psychiatrie, Psychotherapie, Günzstr. 1, 93059, Regensburg, Deutschland.
Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gemeinnützige GmbH, Berg, Deutschland.
Nervenarzt. 2017 Dec;88(12):1428-1434. doi: 10.1007/s00115-017-0439-3.
The symptomatic treatment of multiple sclerosis (MS) nowadays is of similar importance as immunotherapy within a comprehensive concept of therapy of this chronic disease, since it contributes considerably to the reduction of disabilities in activities of daily living as well as social and occupational life. Moreover, symptomatic treatment is of great importance for amelioration of quality of life. Since our last survey of symptomatic MS treatment in 2004 and publication of the guidelines of the German Neurological Society and the Klinisches Kompetenznetz Multiple Sklerose (KKN‑MS) in 2014 several developments within the topics of mobility, bladder and sexual function, vision, fatigue, cognition and rehabilitation took place. These new findings together with further aspects of disease measures and overall treatment strategies of the respective symptoms, as well as treatment goals are introduced in a series of six individual contributions. Here, the symptoms of gait disorders and spasticity will be discussed.
在多发性硬化症（MS）这种慢性病的综合治疗理念中，对症治疗如今与免疫治疗具有同等重要性，因为它对减少日常生活活动以及社交和职业生活中的残疾状况有很大帮助。此外，对症治疗对于改善生活质量也非常重要。自我们2004年上次对MS对症治疗进行调查以及2014年德国神经学会和多发性硬化症临床能力网络（KKN-MS）发布指南以来，在 mobility、膀胱和性功能、视力、疲劳、认知及康复等主题方面有了一些进展。这些新发现连同疾病措施的其他方面以及各症状的整体治疗策略和治疗目标在一系列六篇独立稿件中进行了介绍。在此，将讨论步态障碍和痉挛的症状。
